I partner with life sciences and technology companies to accomplish their general legal objectives, as well as guide them through financing transactions and public company reporting and compliance.
+1 858 550 6034
Sean Clayton's practice focuses on the representation of public and private growth companies in general corporate matters, as well as a wide range of transactions, including public offerings, venture capital financings and M&A.
Download full bio
Inhibrx – $137 Million IPO
Poseida Therapeutics – $224 Million IPO
Pliant Therapeutics - $166 Million IPO
ORIC Pharmaceuticals - $138 Million IPO
Phathom Pharmaceuticals - $209 Million IPO
Mergers & Acquisitions
Don’t know how Cooley does it but they always pull out great attorneys to work with and you are certainly that. We really appreciate your knowledge, experience and counsel through this process.
Stanford Law SchoolJD, Order of the Coif, 2003
University of California, San DiegoBA, Political Science and Economicssumma cum laude, Phi Beta Kappa, 2000
Gossamer Bio – $317 Million IPO
February 21, 2019
ASLAN Pharmaceuticals – $42 Million IPO
June 8, 2018
Vital Therapies – $40 Million Follow-on Offering
March 29, 2017
+1 858 550 6034 office
+1 858 550 6420 fax
4401 Eastgate MallSan Diego, CA 92121-1909